Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a gene-activated matrix for enhanced AAV gene delivery <i>in vitro</i>.

Frontiers in bioengineering and biotechnology·2026
Same author

Functional asymmetry and essential structural roles of PDE6α and PDE6β subunits in rod-photoreceptor integrity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Proximity proteomics reveals a co-evolved LRRK2-regulatory network linked to centrosomes.

EMBO reports·2026
Same author

Light-Activated RPE65 Inhibitors Enable On-Demand Visual Cycle Control.

Journal of the American Chemical Society·2026
Same author

Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton.

Communications biology·2026
Same author

Rationally Designed, Short-Acting RPE65 Inhibitors for Visual Cycle-Associated Retinopathies.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Nov 18, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.8K

Efficient Ocular Delivery of VCP siRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants.

Merve Sen1,2, Marco Bassetto3, Florent Poulhes3

  • 1Centre of Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, 72076 Tübingen, Germany.

Pharmaceutics
|February 10, 2021
PubMed
Summary

Magnetic nanoparticles effectively deliver small interfering RNA (siRNA) to retinal cells, reducing degeneration in an eye disease model. This novel Reverse Magnetofection method shows promise for treating chronic eye conditions.

Keywords:
RHO P23HRNAi therapymagnetic nanoparticlesmagnetofectionocular therapyretinal degenerationretinal organotypic cultureretinitis pigmentosasiRNA delivery

More Related Videos

Transfection of Mouse Retinal Ganglion Cells by in vivo Electroporation
05:26

Transfection of Mouse Retinal Ganglion Cells by in vivo Electroporation

Published on: April 17, 2011

15.9K
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.6K

Related Experiment Videos

Last Updated: Nov 18, 2025

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
06:48

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

21.8K
Transfection of Mouse Retinal Ganglion Cells by in vivo Electroporation
05:26

Transfection of Mouse Retinal Ganglion Cells by in vivo Electroporation

Published on: April 17, 2011

15.9K
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.6K

Area of Science:

  • Ophthalmology
  • Gene Therapy
  • Nanotechnology

Background:

  • RNA-based therapies, including small interfering RNA (siRNA), are crucial for research and treating diseases.
  • The eye's unique anatomy presents challenges for effective siRNA delivery.
  • Autosomal dominant retinitis pigmentosa (adRP) is a chronic eye disease with unmet therapeutic needs.

Purpose of the Study:

  • To evaluate the efficacy and safety of magnetic nanoparticles (MNPs) for delivering siRNA to retinal tissue.
  • To assess the potential of Reverse Magnetofection for treating adRP by targeting valosin-containing protein (VCP).

Main Methods:

  • Utilized magnetic nanoparticles (MNPs) and magnetic force (Reverse Magnetofection) to deliver siRNA targeting VCP into retinal explants.
  • Employed retinal explants from the RHO P23H rat, a model for adRP.
  • Assessed delivery efficiency, cell toxicity, microglial activation, and VCP gene silencing.

Main Results:

  • Achieved safe and efficient delivery of VCP siRNA into all retinal cell layers of explants.
  • Observed no toxicity or microglial activation, indicating a safe delivery method.
  • Demonstrated significant reduction in retinal degeneration following VCP silencing.

Conclusions:

  • Reverse Magnetofection is an effective method for siRNA delivery to retinal tissue.
  • This technique, combined with retinal explants, provides a reliable preclinical platform for ocular RNA-based therapies.
  • VCP targeting via siRNA holds potential for future adRP treatment.